Belzutifan for Kidney Cancer

"No, this study is not actively recruiting participants. The clinical trial was originally posted on 5/2/2018 and last updated on 11/1/2022. There are 4128 other clinical trials currently accepting participants at this time."

"There are currently 16 ongoing trials for the use of Belzutifan globally. The first trial was conducted in 2016 and, although it has only been 5 years since the initial study, 1 additional trial has already been completed."

"Belzutifan's score is a 2. This means that while there is some evidence supporting its safety, none of the available data suggests that it is an effective medication."

"NIH Clinical Center in Bethesda, MD, Huntsman Cancer Institute in Salt Lake City, UT, and University of Pennsylvania Medical Center in Philadelphia are some of the places where this trial is enrolling patients. There are also 8 other sites."

"16 different clinical trials for Belzutifan are ongoing, with 3 of those in Phase 3. The majority of these studies originate from Omaha, Nebraska, but there are 849 research sites total conducting investigations into Belzutifan."

"Belzutifan can be used to ameliorate the symptoms of malignant neoplasms, anemia, sickle cell, and von hippel lindau disease."

"As of right now, this clinical trial has no open positions. However, it is important to note that the date range for this study was from May 2nd, 2018 to November 1st, 2022. If you are looking for other trials enrolling participants with carcinoma or renal cell, there are 4112 and 16 studies respectively that may have open positions."